Bruker Selected as ‘Company of the Year’ by Instrument Business Outlook
01 Abril 2024 - 5:00AM
Business Wire
Bruker Corporation (NASDAQ: BRKR) has been selected as the
Instrument Business Outlook (IBO) ‘Company of the Year’ for 2023.
IBO cited Bruker’s double-digit organic revenue growth in 2023 in
all major regions, and in all business groups, demonstrating a
transformed portfolio and operational strength.
The IBO recognition follows Bruker’s three consecutive years of
double-digit organic revenue growth. The fast growth can be
attributed to the Bruker innovation model, management process and
culture of disciplined entrepreneurialism, which have transformed
the company’s product portfolio and addressable markets for
sustainable above-market growth.
Commenting on the recognition of Bruker as the 2023 winner,
Tanya Samazan, editor-in-chief of IBO, said: “We make our annual
selection based on the criteria of financial and operational
results, new product innovations and notable business developments.
This year, Bruker was our standout choice.”
Frank H Laukien, President and CEO of Bruker,
commented: “We are very pleased to have been recognized by this
respected industry news report in a year when, according to IBO,
‘market conditions proved difficult for the lab tools industry in
general.’ Our dual strategy of Project Accelerate 2.0 and
Operational Excellence has built our company into an emerging
leader in the post-genomic era. As previously stated, for 2024 we
again expect excellent growth, with anticipated 8%-10% constant
exchange rate (CER) revenue growth, well above-market organic
revenue and non-GAAP EPS growth, as foundations for further
expansion.”
Tanya Samazan added: “Bruker was the clear choice for our 2023
Company of the Year, not only because of its solid financial
performance but also through its range of end markets and diverse
product types that allow the company to capitalize on global trends
such as clean energy, 3D chips and single cell proteomics.
Congratulations to a well-deserving winner.”
IBO is an industry newsletter for the laboratory tools market
that delivers the latest business developments, financial data,
executive interviews and insight into market trends and
opportunities. IBO is a publication of SDi, a division of Science
and Medicine Group, which offers custom market research and
strategic advisory services.
About Bruker Corporation – Leader of the Post-Genomic Era
(Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough
post-genomic discoveries and develop new applications that improve
the quality of human life. Bruker’s high performance scientific
instruments and high value analytical and diagnostic solutions
enable scientists to explore life and materials at molecular,
cellular, and microscopic levels. In close cooperation with our
customers, Bruker is enabling innovation, improved productivity,
and customer success in post-genomic life science molecular and
cell biology research, in applied and biopharma applications, in
microscopy and nanoanalysis, as well as in industrial and cleantech
research, and next-gen semiconductor metrology in support of AI.
Bruker offers differentiated, high-value life science and
diagnostics systems and solutions in preclinical imaging, clinical
phenomics research, proteomics and multiomics, spatial and
single-cell biology, functional structural and condensate biology,
as well as in clinical microbiology and molecular diagnostics. For
more information, please visit www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240401187855/en/
Bruker Investor: Justin Ward Sr. Director, Investor
Relations & Corporate Development T: +1 (978) 313-5800 E:
Investor.Relations@bruker.com Bruker Media: Markus Ziegler
Sr. Director and Head of Group Marketing T: +49 172 3733531 E:
pr@bruker.com
Bruker (NASDAQ:BRKR)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Bruker (NASDAQ:BRKR)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024